Akero Therapeutics IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Akero Therapeutics | AKRO - NASDAQ |
$14.00-$16.00 | $16.00 | $16.16 | 5.75 million | 6/20/2019 |
| JP Morgan, Jefferies, Evercore ISI | ||||||
Co-Manager(s): Roth Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-24 Terms Added 2019-06-10 | ||||||
Akero Therapeutics Quote & Chart - Click for current quote - AKRO
IPO Boutique aggregates information on public companies and private companies, such as "AKRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Akero Therapeutics (adapted from Akero Therapeutics prospectus):
They are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AKRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.